GAMMA Investing LLC Has $1.97 Million Stock Holdings in Zoetis Inc. $ZTS

Key Points

• GAMMA Investing LLC increased its stake in Zoetis Inc. by 18.1%, now holding shares valued at approximately $1.97 million.
• Institutional investors own 92.80% of Zoetis stock, indicating a strong interest and investment from major financial entities.
• Zoetis reported a quarterly earnings per share of $1.76, surpassing analysts' expectations, with revenue increasing by 4.2% year-over-year.

GAMMA Investing LLC grew its position in Zoetis Inc. (NYSE:ZTS - Free Report) by 18.1% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,618 shares of the company's stock after purchasing an additional 1,933 shares during the period. GAMMA Investing LLC's holdings in Zoetis were worth $1,968,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after acquiring an additional 189,287 shares during the period. Polen Capital Management LLC raised its holdings in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after acquiring an additional 1,313,653 shares during the period. Northern Trust Corp raised its holdings in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after acquiring an additional 78,508 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after acquiring an additional 109,791 shares during the period. Finally, Brown Advisory Inc. raised its holdings in shares of Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after acquiring an additional 312,746 shares during the period. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Price Performance

Shares of Zoetis stock opened at $144.73 on Tuesday. Zoetis Inc. has a twelve month low of $139.70 and a twelve month high of $197.51. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The company has a 50-day simple moving average of $151.03 and a two-hundred day simple moving average of $156.27. The stock has a market capitalization of $64.14 billion, a price-to-earnings ratio of 24.91, a price-to-earnings-growth ratio of 2.34 and a beta of 0.88.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. During the same quarter in the previous year, the company earned $1.56 EPS. The business's revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Analyst Ratings Changes

A number of brokerages recently commented on ZTS. Argus restated a "buy" rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Piper Sandler raised their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research report on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Finally, Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and decreased their target price for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.